Cellectis And VitamFero Collaborate To Develop Vaccines Against Parasitic Infection

Cellectis (Alternext: ALCLS), the genome engineering specialist, and VitamFero, a biotech company of the Genopole® portfolio developing new vaccines against parasite infections, today announced the signing of a research, development and licensing partnership agreement. This agreement will grant VitamFero access to Cellectis' proprietary meganuclease technology for the design and development of a new generation of living attenuated vaccines.


Under this 5-year agreement, Cellectis will supply VitamFero with preselected meganucleases for initial use in the development of vaccines against parasites responsible for toxoplasmosis, neosporosis, and others.


"Vaccines against these parasite diseases are a major challenge both for public health and the economy, in particular in the veterinary sector," declared Cellectis CEO Andre Choulika. "We are delighted to be working with VitamFero in this field to promote the development of a new application of our technology."


For Pascal Breton, CEO of VitamFero, "This agreement represents an important step forward for our company, by getting access to Cellectis' intellectual propriety and strengthening our technological potential in the modification of the genomes of apicomplex parasites."


Source: Cellectis

Buy Zofran Without Prescription